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Abstract
Hereditary breast cancer comprises 10% of all breast cancers. The most prevalent genes causing this pathology are BRCA1
and BRCA2 (breast cancer early onset 1 and 2), which also predispose to other cancers. Despite the outstanding relevance of
genetic screening of BRCA deleterious variants in patients with a history of familial cancer, this practice is not common in
Latin American public institutions. In this work we assessed mutations in the entire exonic and splice-site regions of BRCA in
39 patients with breast and ovarian cancer and with familial history of breast cancer or with clinical features suggestive for
BRCA mutations by massive parallel pyrosequencing. First we evaluated the method with controls and found 41–485 reads
per sequence in BRCA pathogenic mutations. Negative controls did not show deleterious variants, confirming the suitability
of the approach. In patients diagnosed with cancer we found 4 novel deleterious mutations (c.2805_2808delAGAT and
c.3124_3133delAGCAATATTA in BRCA1; c.2639_2640delTG and c.5114_5117delTAAA in BRCA2). The prevalence of BRCA
mutations in these patients was 10.2%. Moreover, we discovered 16 variants with unknown clinical significance (11 in exons
and 5 in introns); 4 were predicted as possibly pathogenic by in silico analyses, and 3 have not been described previously.
This study illustrates how massive pyrosequencing technology can be applied to screen for BRCA mutations in the whole
exonic and splice regions in patients with suspected BRCA-related cancers. This is the first effort to analyse the mutational
status of BRCA genes on a Mexican-mestizo population by means of pyrosequencing.
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Introduction
About 10% of all breast cancers are of monogenic origin [1].
The most prevalent entity is Hereditary Breast and Ovarian
Cancer (HBOC), an autosomal dominant disease with incomplete
penetrance. The two high-penetrance genes most commonly
mutated in HBOC are the tumor suppressor genes BRCA1 and
BRCA2 (breast cancer, early onset 1 and 2). The BRCA1 gene, localized
at 17q21, and BRCA2, at 13q12, have long coding sequences (5589
and 10254 nt for BRCA1 and BRCA2, respectively) and are
essential components of the double-strand break repair by
homologous recombination system [2]. Almost 3500 deleterious
mutations in these genes have been found in all the coding
sequence [3]. Furthermore BRCA1 and BRCA2 mutation carriers
are also at increased risk of fallopian tubes, pancreatic, prostate
and endometrial cancer [4–6].
The molecular diagnosis of mutations in BRCA genes implies
high degree of clinical suspicion based principally in history of
familial BRCA-related cancers in first- or second-degree relatives,
age of presentation and tumor characteristics (morphological,
immunohistochemical and molecular features) [7]. For patients
with a BRCA mutation, current clinical alternatives include breast
and ovarian screening, prophylactic surgery, and chemopreven-
tion [8]. The approach extends to their family in order to identify
other members at risk to allow the genetic advice, screening and/
or predictive testing [9].
Unfortunately, genetic testing for mutations in BRCA1 and
BRCA2 is not always available in public institutions in developing
countries due to its high cost and limitations in infrastructure. As
BRCA genes have long coding sequences and lack mutation hot
spots, the current strategies for BRCA genotyping typically include
a first step to detect occurring mutations by protein truncation test
(PTT), denaturing high-performance liquid chromatography
(dHPLC), denaturing gradient gel electrophoresis (DGGE) or
high-resolution melting curve analysis (HRMCA); and a final step
to determine the mutation by Sanger sequencing [10]. These
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could be substituted by high throughput, cost efficient testing
methods such as massively parallel sequencing [11,12].
In this work we used massive parallel pyrosequencing to screen
for mutations in the complete coding regions and splice sites of
BRCA genes in Mexican women. We studied 39 patients with
breast and/or ovary cancer and with history of familial cancer and
with early-onset breast cancer, suggestive for BRCA mutations. We
found 4 pathogenic mutations, of which 3 have not been
described. We also identified 16 missense mutations with unknown
deleterious effects. In addition, by a directed sequencing strategy,
we evaluated the presence of the deleterious mutations in the
family members of the patients. Also, we identified family
members with the mutations and with no clinical manifestations
of cancer. These patients began clinical management (that
includes follow-up and prophylactic measures). This work
illustrates how new sequencing technology for screening of
mutations in BRCA genes impacts the familial health scenario
and can be conducted as part of the genetic approach for patients
with familial cancer in public health care institutions.
Methods
Patients
A total of 39 patients were screened. Thirty-five female patients
with breast and/or ovarian cancer and with two or more first- or
second-degree relatives with tumors associated with BRCA
mutations were studied. Two male patients with breast cancer
were included. All patients were clinically approached and a three-
generation genealogy of each family was made. Two patients
without familial cancer history, one with early-onset (age of
diagnosis: 28) breast cancer and one with breast and ovarian
cancer, suggestive for BRCA mutations, were also included.
Patients were fully informed about the study and gave their
written consent. The protocol was approved by the Institutional
Review Boards of the National Cancer Institute of Mexico (http://
www.incan.edu.mx/) and carried out in accordance with the
Figure 1. Quality of the sequencing runs. The percentages of the reads with their associated quality numbers of all runs are plotted.
doi:10.1371/journal.pone.0037432.g001
Table 1. Evaluation of the methodological strategy for the detection of BRCA mutations.
Sample Gene Deleterious Mutation Type of mutation
a
Position
(aa)
Stop codo ´n
position
(aa) Coverage
1
Clinical
relevance
BIC
reported Reference
Control
(+)1
BRCA1 c.4065_4068delTCAA F 1355 1364 41 Yes Yes [13,47–49]
Control
(+)2
BRCA2 c.2808_2811delACAA F 936 958 459 Yes Yes [50]
Control
(+)3
BRCA2 c.9382C.T S 3128 3128 485 Yes Yes [51,52]
Control
(2)1
- None detected - - - - - - -
Control
(2)2
- None detected - - - - - - -
1Number of reads per nucleotide.
aTypes of mutations: F: frameshift; S: stop.
doi:10.1371/journal.pone.0037432.t001
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DNA isolation
Genomic DNA was isolated of peripheral blood with the Magna
Pure System (Roche) following manufacturer instructions. The
integrity of the material was verified by agarose electrophoresis.
Sample quantification was done with the Quant-it Picogreen kit
(Invitrogen) in a QuantiFluor Fluorometer (Promega).
Pyrosequencing
A Sequencing Master library of amplicons covering all the
coding exons and splice sites of BRCA1 and BRCA2 was produced
for each patient using the BRCAMASTR kit (Multiplicom)
following manufacturer instructions. Briefly, 50 ng of gDNA were
used as template in each of 12 multiplex PCR reactions for each
patient. These reactions amplified the complete exonic and splice
sites of BRCA1 and BRCA2. A 1:1000 dilution of the purified PCR
products were re-amplified using molecular identification (MID)
adaptors for each patient. A BRCA amplicon library of each
patient was generated and equivalent concentrations of the
libraries were pooled to generate a Sequencing Master library.
Pyrosequencing of the Master libraries were done in the sense and
anti-sense strands with the 454 GS Junior (Roche) technology.
Data analysis was done with the GS Amplicon Variant Analyzer
software (Roche) comparing against genomic references
NG_005905 and NG_012772 for BRCA1 and BRCA2, respective-
ly. The cDNA references utilized were NM_007294 and
NM_000059 for BRCA1 and BRCA2, respectively. The nomen-
clature used is based on the cDNA sequence and is according to
Human Genome Variation Society (http://www.hgvs.org/). All the
deleterious mutations found were verified by Sanger sequencing of
original patient blood DNA and by restriction analysis when
possible. The putative functional effects of missense variants were
analyzed in silico with PolyPhen-2 (http://genetics.bwh.harvard.edu/
pph2/).
Restriction analysis
The presence of the mutation c.3124_3133delAGCAATATTA
found in patient 11 was verified by restriction analysis of the PCR
product (554 pb) amplified with the primers BRCA1-11.1F:
TCAGAGGCAACGAAACTGGACTCA and BRCA1-11.1R:
CAGCCTATGGGAAGTAGTCATGCA. The mutated allele
lacks the restriction site for SspI (AATATT) and is not cleaved
by this enzyme, while the wild-type allele is cleaved in two
fragments (257 and 297 pb). 500 ng of PCR products were
digested with 1 U of SspI (Fermentas) at 37uC for 4 h in 20 uL.
Ten uL of the reactions were visualized in 1.5% agarose gels.
Results
To analyze the performance of the amplicon strategy for the
sequencing of BRCA genes we carried out an evaluation run with
6 patients’ samples, of which 4 had previously identified mutations
and 2 were negative controls [13]. We used three inclusion criteria
to accept valid mutated sequences: 1) mutation found in forward
and reverse sequences, 2) at least 30% of sequences with the
mutations and 3) at least 20X of sequence coverage of the
amplicons with the mutation. Also we defined three exclusion
criteria: 1) mutations detected in an homopolymeric tract of $6, 2)
mutations found in the last nucleotide of the sequence and with
frequencies of less than 30% and 3) quality score lower than 20 in
forward and reverse reads. Similar criteria have been described
Figure 2. Distribution of homopolymeric tracts across the
reads. The base number signals are plotted against the sequence reads
of the control run.
doi:10.1371/journal.pone.0037432.g002
Table 2. Clinical features of the patients with BRCA mutations.
Sample Age (years) Cancer Type
Age diagnosis
(years)
Familial
cancer history
Tumor Histological
Features
Other Tumor
Features
a
Patient 1 31 Breast cancer 31 Yes Canalicular carcinoma ER positive, PR
positive, Her2/neu
positive
Patient 3 42 Ovarian cancer 33 No Ovarian serous
adenocarcinoma
Not reported
Unilateral Breast cancer 38 Canalicular carcinoma Triple negative
Patient 15 37 Ovarian cancer 24 Yes Ovarian serous
adenocarcinoma
Not reported
Unilateral breast cancer (right) 37 Canalicular carcinoma,
brisk lymphocytic
infiltrate
ER positive, PR
positive and Her2/
neu negative Ki-
67: 5%
Patient 39 44 Bilateral breast cancer 27 Yes Canalicular carcinoma Triple negative
aER = estrogen receptor; PR = progesterone receptor; HER2/neu = human epidermal growth factor receptor 2; Ki-67= antigen KI 67.
doi:10.1371/journal.pone.0037432.t002
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Pyrosequencing of BRCA Mutations on Mexican Women
PLoS ONE | www.plosone.org 5 May 2012 | Volume 7 | Issue 5 | e37432elsewhere [12]. As seen in table 1, we detected all the deleterious
mutations in the positive controls and no pathogenic variants were
found in the negative controls. In the mutations observed the
minimal and maximal coverage was 41 and 485 reads per
nucleotide, respectively. Also in this control experiment more than
70% of all the reads across the whole exon and splice sites had a
quality score (Q) ranging from 36 to 40 (highest score), and low
quality reads with Q.20 were less than 10% (Fig. 1). As expected,
we observed that the majority of these low quality reads were in
homopolymeric tracts, especially of .6 bases. Although present,
these homopolymeric sequences are a negligible number of the
total reads (Fig. 2). With this analysis we concluded that the
strategy used was robust and suitable for its application in the
screening of BRCA mutations in patients’ samples.
We screened for mutations in the whole coding sequence of
BRCA genes in 39 patients with early-onset breast and ovarian
tumors and/or with familial history of cancer, suggestive for BRCA
mutations, as determined by our Clinic of Genetics. The main
clinical characteristics of the patients are listed in table 2 and 3.
After the pyrosequencing analysis and careful examination of the
reads with our criteria of inclusion and exclusion, we found 4
mutations in the BRCA genes (c.2805_2808delAGAT and
c.3124_3133delAGCAATATTA in BRCA1; c.2639_2640delTG
and c.5114_5117delTAAA in BRCA2). All mutations were
predicted to be deleterious because each generated a stop codon
in the open reading frame (Table 4). These pathogenic mutations
were confirmed by Sanger sequencing and the c.3124_3133de-
lAGCAATATTA mutation in BRCA1 was also confirmed by
restriction analysis (Fig 3). In the family of patient 1 (mutation
c.5114_5117delTAAA) we found 10 clinically asymptomatic
carriers (Fig. 4). The family with the c.2639_2640delTG mutation
in BRCA2 (patient 15) had a strong history of cancer, including
laryngeal, gastric, lung and colon cancer in second- and third-
degree relatives in the maternal branch (Fig. 5). In the family with
the c.2805delAGAT mutation in BRCA1 (patient 39), one first-
degree relative had breast and colon cancer (Fig. 6). Interestingly,
3 of the 4 deleterious mutations have not been described
previously. Likewise, we detected 16 genetic variants with
unknown clinical significance (VUS), which included missense
mutations and changes in intronic sequences (Table 5). Four VUS
were predicted to be potentially deleterious by in silico analyzes
(Table 5). Intronic variants that have been evaluated functionally
through in vitro experiments by others were not present [14]. No
Ashkenazi founder mutations were found.
Discussion
Molecular genetic testing of germline mutations in BRCA genes
is not common in public institutions in Latin America due to its
high costs and limitations in infrastructure. Current protocols for
BRCA mutation detection are time consuming and laborious,
which makes difficult their implementation in developing coun-
tries. Also, the polymorphic nature of BRCA genes, their long size
and lack of hot mutation spots highlight the necessity to implement
new high throughput diagnostic methodologies. Almost 10% of
breast cancer is associated to hereditary mutations [15]. Likewise,
the lifetime risk of developing breast cancer is been reported as
high as 80% and 50% for BRCA1 and BRCA2 mutation carriers,
respectively; although it varies between different populations and
ethnicities [16,17]. In this light, BRCA genetic testing is of major
diagnostic relevance not only because it provides a clinical
preventive approach to family members before the development
of cancer, but also can imply novel treatment strategies for affected
patients, such as the use of poly-(ADP–ribose) polymerase
T
a
b
l
e
3
.
C
o
n
t
.
P
a
t
i
e
n
t
3
5
5
2
F
e
m
a
l
e
U
n
i
l
a
t
e
r
a
l
b
r
e
a
s
t
c
a
n
c
e
r
+
N
F
-
1
C
a
n
a
l
i
c
u
l
a
r
c
a
r
c
i
n
o
m
a
E
R
p
o
s
i
t
i
v
e
,
P
R
(
+
)
a
n
d
H
e
r
2
/
n
e
u
(
2
)
4
6
Y
e
s
2
B
r
e
a
s
t
c
a
n
c
e
r
.
L
i
v
e
r
c
a
n
c
e
r
1
s
t
4
9
P
a
t
i
e
n
t
3
6
6
0
F
e
m
a
l
e
U
n
i
l
a
t
e
r
a
l
b
r
e
a
s
t
c
a
n
c
e
r
+
N
F
-
1
C
a
n
a
l
i
c
u
l
a
r
c
a
r
c
i
n
o
m
a
T
r
i
p
l
e
n
e
g
a
t
i
v
e
4
9
Y
e
s
2
B
r
e
a
s
t
c
a
n
c
e
r
.
L
i
v
e
r
c
a
n
c
e
r
1
s
t
4
6
P
a
t
i
e
n
t
3
7
4
0
F
e
m
a
l
e
U
n
i
l
a
t
e
r
a
l
b
r
e
a
s
t
c
a
n
c
e
r
C
a
n
a
l
i
c
u
l
a
r
c
a
r
c
i
n
o
m
a
T
r
i
p
l
e
n
e
g
a
t
i
v
e
3
6
N
o
-
-
-
-
P
a
t
i
e
n
t
3
8
3
9
F
e
m
a
l
e
U
n
i
l
a
t
e
r
a
l
b
r
e
a
s
t
c
a
n
c
e
r
C
a
n
a
l
i
c
u
l
a
r
c
a
r
c
i
n
o
m
a
T
r
i
p
l
e
n
e
g
a
t
i
v
e
3
5
N
o
-
-
-
-
P
a
t
i
e
n
t
3
9
4
4
F
e
m
a
l
e
B
i
l
a
t
e
r
a
l
b
r
e
a
s
t
c
a
n
c
e
r
C
a
n
a
l
i
c
u
l
a
r
c
a
r
c
i
n
o
m
a
T
r
i
p
l
e
n
e
g
a
t
i
v
e
1
s
t
:
2
7
,
2
n
d
:
3
3
Y
e
s
1
B
r
e
a
s
t
a
n
d
c
o
l
o
r
e
c
t
a
l
c
a
n
c
e
r
1
s
t
5
4
E
R
=
e
s
t
r
o
g
e
n
r
e
c
e
p
t
o
r
;
P
R
=
p
r
o
g
e
s
t
e
r
o
n
e
r
e
c
e
p
t
o
r
;
H
E
R
2
/
n
e
u
=
h
u
m
a
n
e
p
i
d
e
r
m
a
l
g
r
o
w
t
h
f
a
c
t
o
r
r
e
c
e
p
t
o
r
2
.
N
A
:
I
n
f
o
r
m
a
t
i
o
n
n
o
t
a
v
a
i
l
a
b
l
e
.
N
F
-
1
:
N
e
u
r
o
f
i
b
r
o
m
a
t
o
s
i
s
t
y
p
e
1
d
o
i
:
1
0
.
1
3
7
1
/
j
o
u
r
n
a
l
.
p
o
n
e
.
0
0
3
7
4
3
2
.
t
0
0
3
Pyrosequencing of BRCA Mutations on Mexican Women
PLoS ONE | www.plosone.org 6 May 2012 | Volume 7 | Issue 5 | e37432inhibitors [18–20]. Additionally, BRCA genetic tests are central
for the determination of founder mutations, which are frequent
deleterious variants that can be screened in the population in first-
line directed studies to reduce costs and accelerate diagnosis
[21,22]. In the Mexican population no founder mutations have
been described.
In these work we analysed BRCA full exome and splice site
mutations by massive parallel pyrosequencing. In the evaluation of
the method, we found all the mutations present in previously
characterized positive controls; negative controls showed no
variants. The coverage of the sequences for the mutations varied
from 41 to 485X, with quality scores of 20–40 in 95% of the reads
throughout all the exonic and splice sites regions. These results led
us to evaluate mutations in patients with hereditary breast and
ovarian cancer syndrome and in patients with clinical features
suggestive for BRCA deleterious mutations. In these analyses we
Table 4. Detection of BRCA deleterious mutations in patients.
Sample Gene Mutation
Type of
mutation
Position
(aa)
Stop
position
(aa) Coverage
1
Clinical
relevance
BIC
reported References
Patient 3 BRCA1 c.3124_3133delAGCAATATTA F 1042 1047 77 Yes No Not reported
Patient 39 BRCA1 c.2805_2808del AGAT F 935 998 21 Yes No Not reported
Patient 1 BRCA2 c.5114_5117delTAAA F 1705 1710 70 Yes Yes [53]
Patient 15 BRCA2 c.2639_2640delTG F 880 888 29 Yes No Not reported
1Number of reads per nucleotide.
2Types of mutations: F: frameshift; S: stop.
doi:10.1371/journal.pone.0037432.t004
Figure 3. Restriction analysis of the mutation c.3124_3133de-
lAGCAATATTA found in patient 3. PCR products encompassing the
mutation were digested with SspI (see methods). The mutated allele has
lost the SspI site and is not cleaved by the enzyme, while the wild-type
allele is cut in two fragments. Lanes: 1) wild-type control PCR product
not digested, 2) patient 11 PCR product not digested, 3) wild-type
control PCR product digested, 4) patient 11 PCR product digested. Mut:
mutated; Wt: wild-type.
doi:10.1371/journal.pone.0037432.g003
Figure 4. Genealogy of the family 1 carrier of the deleterious mutation c.5114_5117delTAAA in BRCA2. Index patient is denoted with an
arrow. Individuals with cancer are represented with in dark circles or with dark squares; the type of cancer is indicated as follows: Bla: Bladder cancer;
Br: Unilateral Breast Cancer; B-Br: Bilateral breast cancer. Current age or known ages of cancer diagnosis and decease are showed. Numbers inside the
rhombi indicate quantity of relatives. Asymptomatic carriers are represented with a midline. Unaffected family members confirmed by the predictive
molecular testing are shown with a W (wild type).
doi:10.1371/journal.pone.0037432.g004
Pyrosequencing of BRCA Mutations on Mexican Women
PLoS ONE | www.plosone.org 7 May 2012 | Volume 7 | Issue 5 | e37432found 4 (10.2%) BRCA mutations in the 39 patients, which is very
similar to the prevalence reported by other studies of families with
hereditary cancer in Latin America [13,23,24]. All the mutations
found in these patients have not been previously described and are
not reported in the Breast Cancer Information core (BIC) and
NCBI variant databases, which is in concordance with the
polymorphic nature of these genes [25]. Interestingly, one of
these mutations was in a patient with no history of familial cancer,
but with strong suggestive clinical manifestations of a BRCA
mutation, such as early-onset breast cancer [26]. This result
highlights the necessity to extend the screening for BRCA
mutations also to candidate patients with no history of familial
cancer, which is in concordance with reports that described that
30–50% of BRCA mutation carriers have not family history of
breast and ovarian cancer [27,28]. Remarkably, we found 10
clinically asymptomatic BRCA2 mutation (c.5114_5117delTAAA)
carriers in family 1, which reflects the incomplete penetrance
associated with different BRCA mutations and that there are other
risk factors associated with the penetrance of BRCA mutations
[29–32]. In this study we used massive parallel pyrosequencing
because its capacity to screen the whole exonic and splice site
regions of BRCA1 and BRCA2 in up to 8 samples per run and its
high depth of sequence, which provides more sensitivity for
mutation detection than conventional Sanger sequencing and
makes this strategy cost-effective [33]. Also, these advantages offer
great benefit to the diagnostic scenario, comparing to other
methods. However, this technology has intrinsic limitations,
namely the detection of whole exon deletions and the identifica-
tion of mutations in homopolymeric tracts longer than 6 bases.
Since the frequency of exon deletion and large genomic
rearrangements is population-dependent and has been described
as 1–30% in BRCA-associated cancers, it is determinant to further
Figure 5. Genealogy of the family 15 carrier of the deleterious mutation c.2639_2640delTG in BRCA2. Individuals with cancer are
represented with dark circles or with dark squares; the type of cancer is indicated as follows: Br: unilateral breast cancer; Cr: colorectal cancer; NE: Not
especified neoplasia; L: lung cancer; La: laryngeal cancer; Ga: gastric cancer. Index patient is denoted with an arrow. Current age or known ages of
cancer diagnosis and decease are showed. Numbers inside the rhombi indicate quantity of first-degree relatives. Asymptomatic carriers are
represented with a midline.
doi:10.1371/journal.pone.0037432.g005
Figure 6. Genealogy of the family 39 carrier of the deleterious mutation c.2805_2808delAGAT in BRCA1. Index patient is denoted with
an arrow. Individuals with cancer are represented in dark; the type of cancer is indicated as follows: Br: unilateral breast cancer; Cr: colorectal cancer.
Current age or known ages of cancer diagnosis and decease are showed. Numbers inside the rhombi indicate quantity of relatives.
doi:10.1371/journal.pone.0037432.g006
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mentary methods, such as Multiplex Ligation-dependent Probe
Amplification analysis [34–36]. Also the evaluation of homopol-
ymeric tract variants, which comprise 12 stretches longer than 6 nt
in the BRCA1 and BRCA2 coding sequences, should be assessed
with alternative methods such as high-resolution-melting-curve-
analysis [37]. When negative, these analyzes would rule out the
BRCA etiology of the tumor. Thus, in these patients with clear
familial history of cancer, the evaluation of mutations in other
genes, like PALB2, CHEK2 and RAD51C, should also be
considered [38–41]. This could be the case of some of the families
of this study, in which we screened 35 patients with a clear familial
history of cancer, but we only found 3 patients with mutations in
BRCA. Additionally, the presence of VUS could be related to
pathogenic effects at the level of mRNA processing, stability,
translation and protein function, as has been described in BRCA1
and other genes [42–46]. The effect of VUS is subject of great
interest as their presence exceeds mutations in patients with
familial cancer; however, their functional evaluation is far from
being a common diagnostic practice. In this regard, the functional
evaluation of some VUS in the BRCA genes has showed that
single nucleotide variations in introns can influence mRNA
processing, producing exon skipping and aberrant out of frame
mRNA forms [14]. We found 16 not previously described VUS,
especially in patients without deleterious BRCA variants and 4
were predicted to be pathogenic by computational analyses.
Functional studies must be undertaken to evaluate their effects. In
this concern, we foresee that new routine methods will soon be
accessible to determine the molecular and pathological relevance
of these variants.
In summary, this work illustrates how hole exonic and splice site
massive parallel pyrosequencing can be used as a diagnostic
strategy to determine BRCA mutations. Its use circumvents the
laborious and time-consuming efforts of the current methodolo-
gies. With this technology we found 4 mutations and 16 VUS in
our series of patients with familial cancer, which highlights the
relevance of this approach as a diagnostic tool and suggests it could
be used as a routine practice in public health institutions.
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Table 5. Variants of uncertain significance (VUS) detected in patients.
Patient Gene Localization Variant
Type of
Mutation1
1
Clinical
Relevance
PolyPhen2
prediction
2
BIC
Reported
2, 26, 31, 33 BRCA2 Exon 27 p.I3412V M VUS B Yes
5, 26, 30 BRCA1 Exon 11 p.Q356R M VUS PD Yes
6 BRCA2 Exon 11 p.H1561N M VUS PD Yes
6 BRCA2 Exon 11 p.V2138F M VUS B Yes
7 BRCA1 Exon 11 p.S1040N M VUS B Yes
10, 13, 14,
18, 26, 27,
28, 30, 31, 39
BRCA1 Intron 1 c.219T.C Ts VUS - Yes
10, 11, 17 BRCA1 Exon 11 p.K1183R M Not reported B No
10, 15, 16, 17BRCA2 Intron 11 c.6841+80del TTAA D VUS - Yes
12, 17 BRCA1 Intron 7 c.442234C.T Ts VUS - Yes
12 BRCA1 Exon 11 p.D1344G M VUS PD Yes
16 BRCA2 Exon 11 p.T1915M M VUS B Yes
17 BRCA1 Exon 12 p.K1489E M Not reported B No
18, 20, 39 BRCA1 Intron 12 c.40972141A.C Tv VUS - Yes
18 BRCA1 Intron 14 c.4485264C.G Tv VUS - Yes
19, 20, 21,
24, 27, 28, 31
BRCA2 Exon 15 p.I2490T M VUS B Yes
21 BRCA1 Exon 23 p.V1810V S Not reported B No
30 BRCA1 Exon 23 p.V1804D M VUS B Yes
30 BRCA2 Exon 11 p.S1733S S VUS B Yes
30 BRCA2 Exon 21 K2950N M VUS PD Yes
1D: deletion; M: missense mutation; S: synonimous mutation; Ts: transition; Tv: transvertion.
2B: benign; PD: probably damaging.
doi:10.1371/journal.pone.0037432.t005
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